Get started
Author

Grant McCarthy

Observed names: G. McCarthy, McCarthy, Grant
ORCID: 0000-0001-8292-8598
Observed ORCID: 0000-0001-8292-8598
OpenAlex ID: A5083764815
Patient-reported health state utilities in metastatic gastroenteropancreatic neuroendocrine tumours – an analysis based on the CLARINET study
2017 · Yang Meng, Grant McCarthy, et al. · Health and Quality of Life Outcomes · 14
PDF
The Challenge for Orphan Drugs Remains: Three Case Studies Demonstrating the Impact of Changes to NICE Methods and Processes and Alternative Mechanisms to Value Orphan Products
2022 · Dawn Lee, Grant McCarthy, et al. · PharmacoEconomics - Open · 7
PDF
Intravitreal Ranibizumab for the Treatment of Visual Impairment Due to Choroidal Neovascularization Associated with Rare Diseases: Cost-Effectiveness in the UK
2019 · Grant McCarthy, Elisabetta Fenu, et al. · Advances in Therapy · 6
Cost-effectiveness of pembrolizumab for previously treated MSI-H/dMMR solid tumours in the UK
2024 · Grant McCarthy, Kate Young, et al. · Journal of Medical Economics · 5
Cost–effectiveness of brentuximab vedotin for the treatment of cutaneous T-cell lymphoma
2021 · Tanja Podkonjak, Holly Cranmer, et al. · Journal of Comparative Effectiveness Research · 3
Q-TWiST analysis of pembrolizumab plus trastuzumab and chemotherapy for patients with metastatic HER2-positive gastric or gastroesophageal junction (G/GEJ) adenocarcinoma in the KEYNOTE-811 trial.
2025 · Sun Young Rha, Cedric Revil, et al. · Journal of Clinical Oncology · 1
The Impact of the Approach to Accounting for Age and Sex in Economic Models on Predicted Quality-Adjusted Life-Years
2024 · Dawn Lee, Rose Hart, et al. · Applied Health Economics and Health Policy · 1
Pcn472 Patient Reported Health State Utilities in Cutaneous T-cell Lymphoma (ctcl) - an Analysis of Eq-5d and Skindex-29 Data Collected From the Alcanza Trial
2019 · T. Podkonjak, G. McCarthy, et al. · Value in Health · 1
PDF
Msr167 a Landscape Assessment of the Statistical and Economic Modeling of Cure in Oncology
2026 · Elizabeth Wehler, Hongtao Zhang, et al. · Value in Health
Extrapolation of Time-to-Event Survival Outcomes of Histology-Independent Therapies Using a Bayesian Hierarchical Model
2026 · Jan Mikelson, Richard Birnie, et al. · Medical Decision Making
PDF
EE350 Cost-Effectiveness of Pembrolizumab for Previously treated MSI-H/dMMR Solid Tumors in Canada
2025 · François-Xavier Houde, Cédric Joyal, et al. · Value in Health
EE389 Cost-Effectiveness of Pembrolizumab as First-Line Treatment for Patients with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Unresectable or Metastatic Colorectal Cancer (CRC) from Public Payer Perspective in Brazil
2025 · Monica M. Rojas, Mariana Rosim, et al. · Value in Health
Quality-adjusted time without symptoms of disease or toxicity (Q-TWiST) analysis of pembrolizumab (pembro) versus chemotherapy (chemo) in microsatellite instability–high (MSI-H)/mismatch repair–deficient (dMMR) metastatic colorectal cancer (mCRC) in the KEYNOTE-177 trial.
2025 · Elena Elez, Popova Natalia, et al. · Journal of Clinical Oncology
Use of Real-World Data to Support Economic Evaluations of Tumor-Agnostic Therapies: Challenges Remain
2025 · Kate Young, Grant McCarthy, et al. · Value in Health
PDF
CO99 Validation of Overall Survival (OS) Extrapolations Using 5-Year Follow-up Data From the Keynote-177 MSI-H/dMMR Metastatic Colorectal Cancer (mCRC) Study
2024 · G. McCarthy, G. Baluni, et al. · Value in Health
PDF
Validation of cost-effectiveness of trifluridine/tipiracil versus best supportive care and regorafenib for previously treated metastatic colorectal cancer in the UK using phase IIIb PRECONNECT early access clinical trial data in the real world setting.
2019 · Javier Sabater, Lewis Ralph, et al. · Journal of Clinical Oncology
VP133 Patient-Reported Health State Utilities In Neuroendocrine Tumours
2017 · Yang Meng, Grant McCarthy, et al. · International Journal of Technology Assessment in Health Care
PDF
Works count: 18
Citation count: 38
H-index: 4
I10-index: 1
Year
Topic
Type